Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma ; volume:14 ; number:1 ; day:28 ; month:11 ; year:2024 ; pages:1-7 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (28.11.2024), 1-7, 12.2024
- Urheber
-
Epperla, Narendranath
Lucero, Melanie
Bailey, Tom
Mirams, Laura
Cheung, Jolenta
Amet, Mona
Milligan, Gary
Chen, Lei
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01195-4
- URN
-
urn:nbn:de:101:1-2502132112511.483514133204
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Epperla, Narendranath
- Lucero, Melanie
- Bailey, Tom
- Mirams, Laura
- Cheung, Jolenta
- Amet, Mona
- Milligan, Gary
- Chen, Lei
- SpringerLink (Online service)
Ähnliche Objekte (12)
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
CAR T-cell therapy in diffuse large B-cell lymphoma
Hemophagocytic lymphohistiocytosis complicating a T-cell rich B-cell lymphoma
Diffuse Large B-Cell Lymphoma with Aberrant Coexpression of CD5 and CD8 T-Cell Markers
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Relapsed/refractory diffuse large b-cell lymphoma: is there still a role for autologous stem cell transplantation in the CAR T-cell era?
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia
Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
CAR T-cell therapy in diffuse large B-cell lymphoma
Hemophagocytic lymphohistiocytosis complicating a T-cell rich B-cell lymphoma
Diffuse Large B-Cell Lymphoma with Aberrant Coexpression of CD5 and CD8 T-Cell Markers
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Relapsed/refractory diffuse large b-cell lymphoma: is there still a role for autologous stem cell transplantation in the CAR T-cell era?
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia
Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?
Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
CAR T-cell therapy in diffuse large B-cell lymphoma
Hemophagocytic lymphohistiocytosis complicating a T-cell rich B-cell lymphoma
Diffuse Large B-Cell Lymphoma with Aberrant Coexpression of CD5 and CD8 T-Cell Markers
Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Relapsed/refractory diffuse large b-cell lymphoma: is there still a role for autologous stem cell transplantation in the CAR T-cell era?
Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia
Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?